Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 74.87 USD 0.65% Market Closed
Market Cap: 11.9B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Operating Margin
Bio-Techne Corp

21.4%
Current
25%
Average
2.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
21.4%
=
Operating Profit
248.5m
/
Revenue
1.2B

Operating Margin Across Competitors

Country US
Market Cap 11.8B USD
Operating Margin
21%
Country US
Market Cap 1.3T USD
Operating Margin
14%
Country US
Market Cap 196.2B USD
Operating Margin
17%
Country US
Market Cap 170.9B USD
Operating Margin
21%
Country KR
Market Cap 67.6T KRW
Operating Margin
31%
Country CH
Market Cap 38.5B CHF
Operating Margin
13%
Country US
Market Cap 38.6B USD
Operating Margin
25%
Country US
Market Cap 36.5B USD
Operating Margin
14%
Country US
Market Cap 26.7B USD
Operating Margin
28%
Country US
Market Cap 23.2B USD
Operating Margin
20%
Country US
Market Cap 23B USD
Operating Margin
29%
No Stocks Found

Bio-Techne Corp
Glance View

Market Cap
11.8B USD
Industry
Life Sciences Tools & Services

Bio-Techne Corp. stands at the forefront of scientific progress, intertwining innovation with essential biotechnology solutions. Founded in 1976 and headquartered in Minneapolis, the company has evolved from its roots in producing protein research reagents to a diversified powerhouse, supporting the life sciences and clinical diagnostics sectors. Bio-Techne's expansive portfolio encompasses cutting-edge tools and technologies allowing researchers to delve deeper into cellular analysis, gene expression, and molecular diagnostics. With brands like R&D Systems, Novus Biologicals, and ProteinSimple under its belt, the company empowers scientists worldwide to unlock new discoveries, simulate complex biological processes, and ultimately contribute to advancements in healthcare and life sciences. For investors, Bio-Techne presents a compelling opportunity as it operates in a rapidly growing market fueled by increasing demand for precision medicine and advanced research capabilities. The company has demonstrated robust financial performance, marked by consistent revenue growth and healthy profit margins, driven by its commitment to research and development. As Bio-Techne continues to expand its product offerings and enhance its technological capabilities through strategic acquisitions, it stands poised to capture greater market share and drive shareholder value. With a seasoned management team guided by a focus on innovation and customer-centric solutions, Bio-Techne is not just responding to market trends but actively shaping the future of biotechnology.

TECH Intrinsic Value
55.32 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
21.4%
=
Operating Profit
248.5m
/
Revenue
1.2B
What is the Operating Margin of Bio-Techne Corp?

Based on Bio-Techne Corp's most recent financial statements, the company has Operating Margin of 21.4%.